Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Stock Has Average Price Target of $17.67 According to Analysts

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $17.67.

AUPH has been the topic of a number of analyst reports. Wall Street Zen cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Royal Bank Of Canada upped their price target on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th. Bloom Burton raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 26th.

Aurinia Pharmaceuticals Stock Down 1.2%

Shares of AUPH opened at $16.22 on Monday. Aurinia Pharmaceuticals has a 1 year low of $10.90 and a 1 year high of $19.25. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97. The stock has a 50 day simple moving average of $15.98 and a two-hundred day simple moving average of $15.81. The firm has a market cap of $2.16 billion, a P/E ratio of 7.08 and a beta of 1.40.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.04. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. The firm had revenue of $58.57 million during the quarter, compared to analyst estimates of $80.45 million. On average, analysts forecast that Aurinia Pharmaceuticals will post 0.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of AUPH. Allworth Financial LP raised its position in Aurinia Pharmaceuticals by 34.9% during the 2nd quarter. Allworth Financial LP now owns 3,307 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 855 shares during the last quarter. First Trust Advisors LP grew its position in shares of Aurinia Pharmaceuticals by 15.5% in the 1st quarter. First Trust Advisors LP now owns 14,065 shares of the biotechnology company’s stock worth $208,000 after buying an additional 1,883 shares during the last quarter. Nykredit A S bought a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter worth approximately $35,000. Global Retirement Partners LLC purchased a new position in shares of Aurinia Pharmaceuticals during the second quarter valued at approximately $41,000. Finally, Strs Ohio increased its stake in shares of Aurinia Pharmaceuticals by 4.6% during the first quarter. Strs Ohio now owns 56,500 shares of the biotechnology company’s stock valued at $837,000 after buying an additional 2,500 shares during the period. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s primary product is Lupkynis (voclosporin), an oral calcineurin inhibitor approved for use in combination with background immunosuppressive therapy to treat adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Lupkynis is designed to help control the underlying immune response associated with lupus nephritis and reduce the risk of progressive kidney damage.